- Home
- FLO vs KNSA Comparison
FLO vs KNSA Comparison
Compare FLO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLO
- KNSA
- Stock Information
- Founded
- FLO 1919
- KNSA 2015
- Country
- FLO United States
- KNSA United Kingdom
- Employees
- FLO N/A
- KNSA N/A
- Industry
- FLO Packaged Foods
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- FLO Consumer Staples
- KNSA Health Care
- Exchange
- FLO Nasdaq
- KNSA Nasdaq
- Market Cap
- FLO 3.2B
- KNSA 2.6B
- IPO Year
- FLO N/A
- KNSA 2018
- Fundamental
- Price
- FLO $13.30
- KNSA $35.92
- Analyst Decision
- FLO Hold
- KNSA Strong Buy
- Analyst Count
- FLO 4
- KNSA 6
- Target Price
- FLO $16.50
- KNSA $40.83
- AVG Volume (30 Days)
- FLO 4.2M
- KNSA 392.6K
- Earning Date
- FLO 11-07-2025
- KNSA 10-28-2025
- Dividend Yield
- FLO 7.44%
- KNSA N/A
- EPS Growth
- FLO 71.08
- KNSA N/A
- EPS
- FLO 1.04
- KNSA 0.07
- Revenue
- FLO $5,098,751,000.00
- KNSA $529,332,000.00
- Revenue This Year
- FLO $4.22
- KNSA $37.21
- Revenue Next Year
- FLO $0.08
- KNSA $11.99
- P/E Ratio
- FLO $12.79
- KNSA $542.28
- Revenue Growth
- FLO N/A
- KNSA 56.18
- 52 Week Low
- FLO $13.19
- KNSA $17.82
- 52 Week High
- FLO $23.87
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- FLO 26.25
- KNSA 60.14
- Support Level
- FLO $14.42
- KNSA $35.29
- Resistance Level
- FLO $13.79
- KNSA $37.34
- Average True Range (ATR)
- FLO 0.35
- KNSA 1.00
- MACD
- FLO -0.12
- KNSA -0.15
- Stochastic Oscillator
- FLO 5.64
- KNSA 65.30
About FLO Flowers Foods Inc.
Flowers Foods Inc is an American company producing bakery food for retail and foodservice across the United States. The product portfolio includes fresh breads, buns, rolls, snack cakes, and tortillas. The company distributes to supermarkets, convenience stores, and restaurants. The key brands are Nature's Own, Wonder, Tastykake, Canyon Bakehouse, DKB.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.